Mohamed Adil
Overview
Explore the profile of Mohamed Adil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adil M, Kolarova T, Doebley A, Chen L, Tobey C, Galipeau P, et al.
Nat Med
. 2025 Feb;
PMID: 39939524
Preeclampsia is characterized by placental dysfunction and results in significant morbidity, but reliable early prediction remains challenging. We investigated whether clinically obtained prenatal cell-free DNA (cfDNA) screening (PDNAS) using whole-genome...
2.
Ajkunic A, Sayar E, Roudier M, Patel R, Coleman I, De Sarkar N, et al.
NPJ Precis Oncol
. 2024 May;
8(1):104.
PMID: 38760413
Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins,...
3.
Hiatt J, Doebley A, Arnold H, Adil M, Sandborg H, Persse T, et al.
Sci Adv
. 2024 Apr;
10(15):eadk2082.
PMID: 38598634
We report an approach for cancer phenotyping based on targeted sequencing of cell-free DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of transcription factors (TFs), such...
4.
Franceschini G, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S, et al.
Cancer Discov
. 2024 Jan;
14(3):424-445.
PMID: 38197680
Significance: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation...
5.
Ajkunic A, Sayar E, Roudier M, Patel R, Coleman I, De Sarkar N, et al.
Res Sq
. 2024 Jan;
PMID: 38196594
Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To fully capitalize on the potential impact of drugs targeting surface...
6.
Sayar E, Patel R, Coleman I, Roudier M, Zhang A, Mustafi P, et al.
JCI Insight
. 2023 Feb;
8(7).
PMID: 36821396
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC)....
7.
Doebley A, Ko M, Liao H, Cruikshank A, Santos K, Kikawa C, et al.
Nat Commun
. 2023 Jan;
14(1):403.
PMID: 36697405
No abstract available.
8.
Doebley A, Ko M, Liao H, Cruikshank A, Santos K, Kikawa C, et al.
Nat Commun
. 2022 Dec;
13(1):7475.
PMID: 36463275
Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help guide clinical precision oncology. Here we develop Griffin, a framework for profiling nucleosome protection and accessibility from...
9.
De Sarkar N, Patton R, Doebley A, Hanratty B, Adil M, Kreitzman A, et al.
Cancer Discov
. 2022 Nov;
13(3):632-653.
PMID: 36399432
Significance: This study provides insights into the dynamics of nucleosome positioning and gene regulation associated with cancer phenotypes that can be ascertained from ctDNA. New methods for classification in phenotype...
10.
Lidberg K, Muthusamy S, Adil M, Mahadeo A, Yang J, Patel R, et al.
J Am Soc Nephrol
. 2022 Feb;
33(5):949-965.
PMID: 35197326
Background: The kidneys efficiently filter waste products while retaining serum proteins in the circulation. However, numerous diseases compromise this barrier function, resulting in spillage of serum proteins into the urine...